Evidence map›Paper›PMID 37961521›Full record

ArticleResearch square2023

The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods.

Emre Uygur, Ceren Sezgin, Yasemin Parlak, Kadriye Busra Karatay, Bilal Arikbasi, Ugur Avcibasi, Turkay Toklu, Sabri Barutca, Coskun Harmansah, Tevfik Sinan Sozen and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Emre UygurManisa Celal Bayar University: Manisa Celal Bayar Universitesi.ORCID 0000-0002-8695-8759
Ceren SezginManisa State Hospital: Manisa Devlet Hastanesi.
Yasemin ParlakManisa Celal Bayar University: Manisa Celal Bayar Universitesi.
Kadriye Busra KaratayEge University Institute of Nuclear Sciences: Ege Universitesi Nukleer Bilimler Enstitusu.
Bilal ArikbasiManisa State Hospital: Manisa Devlet Hastanesi.
Ugur AvcibasiManisa Celal Bayar Üniversitesi: Manisa Celal Bayar Universitesi.
Turkay TokluYeditepe University: Yeditepe Universitesi.
Sabri BarutcaAdnan Menderes Üniversitesi Tıp Fakültesi: Adnan Menderes Universitesi Tip Fakultesi.
Coskun HarmansahEge University: Ege Universitesi.
Tevfik Sinan SozenGazi University Faculty of Medicine: Gazi Universitesi Tip Fakultesi.
Stephan MausSaarland University Hospital and Saarland University Faculty of Medicine: Universitatsklinikum des Saarlandes und Medizinische Fakultat der Universitat des Saarlandes.
Howard ScherMemorial Sloan-Kettering Cancer Center Inpatient Hospital and Main Campus: Memorial Sloan Kettering Cancer Center.
Omer ArasMemorial Sloan-Kettering Cancer Center Inpatient Hospital and Main Campus: Memorial Sloan Kettering Cancer Center.
Fikriye Gul GumuserManisa Celal Bayar University: Manisa Celal Bayar Universitesi.
Fazilet Zumrut Biber MuftulerEge University Institute of Nuclear Sciences: Ege Universitesi Nukleer Bilimler Enstitusu.
Manisa Celal Bayar University · TREge University · TRMemorial Sloan Kettering Cancer Center · USSivas State Hospital · TRAdnan Menderes University · TRGazi Hastanesi · TRUniversitätsklinikum des Saarlandes · DEYeditepe University · TR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Prostate cancer (PC) is the most common type of cancer in elderly men, with a positive correlation with age. As resistance to treatment has developed, particularly in the progressive stage of the disease and in the presence of microfocal multiple bone metastases, new generation radionuclide therapies have emerged. Recently, [ Results: In this study, Terbium-161 [ Conclusions: The results suggest that [

Indexed as

prostate cancerPSMA-617Terbium-161 [161Tb]Tb

Identifiers

PMID37961521
PMCPMC10635383
OpenAlexW4388016929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.